FATE – Fate Therapeutics, Inc.
Fate Therapeutics, Inc.FATE
$1.31Name : Fate Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $152,305,120.00
EPSttm : -1.15
Fate Therapeutics, Inc.
$1.31
5.65%$0.07
FATE — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
8.95
Margin Of Safety %
Put/Call OI Ratio
0.11
EPS Next Q Diff
-0.01
EPS Last/This Y
EPS This/Next Y
0.1
Price
1.32
Target Price
4.94
Analyst Recom
2
Performance Q
24.76
Upside
-1,241.2%
Beta
2.24
Ticker: FATE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-17 | FATE | 1.135 | 0.10 | 1.20 | 7579 |
| 2026-03-18 | FATE | 1.055 | 0.10 | 0.45 | 7580 |
| 2026-03-19 | FATE | 1.08 | 0.10 | 1.67 | 7668 |
| 2026-03-20 | FATE | 1.11 | 0.10 | 0.04 | 7672 |
| 2026-03-23 | FATE | 1.16 | 0.10 | 0.04 | 6940 |
| 2026-03-24 | FATE | 1.14 | 0.10 | 0.08 | 6974 |
| 2026-03-25 | FATE | 1.22 | 0.10 | 4.00 | 6921 |
| 2026-03-26 | FATE | 1.225 | 0.11 | 0.11 | 6958 |
| 2026-03-27 | FATE | 1.18 | 0.11 | 0.31 | 6981 |
| 2026-03-30 | FATE | 1.135 | 0.11 | 0.01 | 6984 |
| 2026-03-31 | FATE | 1.2 | 0.11 | 0.29 | 7095 |
| 2026-04-01 | FATE | 1.235 | 0.11 | 0.13 | 7099 |
| 2026-04-02 | FATE | 1.215 | 0.11 | 0.00 | 7072 |
| 2026-04-06 | FATE | 1.195 | 0.11 | 1.00 | 6915 |
| 2026-04-08 | FATE | 1.185 | 0.11 | 10.43 | 6923 |
| 2026-04-09 | FATE | 1.27 | 0.11 | 2.96 | 6929 |
| 2026-04-13 | FATE | 1.31 | 0.11 | 0.04 | 7098 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-17 | FATE | 1.13 | 13.7 | - | -1.16 |
| 2026-03-18 | FATE | 1.05 | 13.7 | - | -1.16 |
| 2026-03-19 | FATE | 1.08 | 13.7 | - | -1.16 |
| 2026-03-20 | FATE | 1.11 | 13.7 | - | -1.16 |
| 2026-03-23 | FATE | 1.16 | 13.7 | - | -1.16 |
| 2026-03-24 | FATE | 1.14 | 13.7 | - | -1.16 |
| 2026-03-25 | FATE | 1.22 | 13.7 | - | -1.16 |
| 2026-03-26 | FATE | 1.23 | 13.7 | - | -1.16 |
| 2026-03-27 | FATE | 1.18 | 13.7 | - | -1.16 |
| 2026-03-30 | FATE | 1.13 | 13.3 | - | -1.15 |
| 2026-03-31 | FATE | 1.21 | 13.3 | - | -1.15 |
| 2026-04-01 | FATE | 1.23 | 13.3 | - | -1.15 |
| 2026-04-02 | FATE | 1.21 | 13.3 | - | -1.15 |
| 2026-04-06 | FATE | 1.20 | 13.3 | - | -1.15 |
| 2026-04-07 | FATE | 1.16 | 13.3 | - | -1.15 |
| 2026-04-08 | FATE | 1.19 | 13.3 | - | -1.15 |
| 2026-04-09 | FATE | 1.28 | 13.3 | - | -1.15 |
| 2026-04-10 | FATE | 1.24 | 13.3 | - | -1.15 |
| 2026-04-13 | FATE | 1.32 | 13.3 | - | -1.15 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-17 | FATE | -0.26 | -0.29 | 8.69 |
| 2026-03-18 | FATE | -0.26 | -0.29 | 8.69 |
| 2026-03-19 | FATE | -0.26 | -0.29 | 8.69 |
| 2026-03-20 | FATE | -0.26 | -0.29 | 8.69 |
| 2026-03-23 | FATE | -0.26 | -0.29 | 8.69 |
| 2026-03-24 | FATE | -0.26 | -0.29 | 8.69 |
| 2026-03-25 | FATE | -0.26 | -0.29 | 8.46 |
| 2026-03-26 | FATE | -0.26 | -0.29 | 8.46 |
| 2026-03-27 | FATE | -0.26 | -0.29 | 8.46 |
| 2026-03-30 | FATE | -0.26 | -0.15 | 8.46 |
| 2026-03-31 | FATE | -0.26 | -0.15 | 8.46 |
| 2026-04-01 | FATE | -0.26 | -0.15 | 8.46 |
| 2026-04-02 | FATE | -0.26 | -0.15 | 8.46 |
| 2026-04-06 | FATE | -0.26 | -0.17 | 8.46 |
| 2026-04-07 | FATE | -0.26 | -0.17 | 8.46 |
| 2026-04-08 | FATE | -0.26 | -0.17 | 8.46 |
| 2026-04-09 | FATE | -0.26 | -0.17 | 8.46 |
| 2026-04-10 | FATE | -0.26 | -0.17 | 8.46 |
| 2026-04-13 | FATE | -0.26 | -0.13 | 8.95 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.27
Avg. EPS Est. Current Quarter
-0.28
Avg. EPS Est. Next Quarter
-0.28
Insider Transactions
-0.26
Institutional Transactions
-0.13
Beta
2.24
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
14
Growth Score
31
Sentiment Score
48
Actual DrawDown %
98.7
Max Drawdown 5-Year %
-99.3
Target Price
4.94
P/E
Forward P/E
PEG
P/S
22.9
P/B
0.73
P/Free Cash Flow
EPS
-1.15
Average EPS Est. Cur. Y
-1.15
EPS Next Y. (Est.)
-1.05
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-2051.08
Relative Volume
1.42
Return on Equity vs Sector %
-93.1
Return on Equity vs Industry %
-76.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
◆
FATE
Healthcare
$1.31
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
57.2
Range 1M
81.7%
Sup Dist
7.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
1.7%
EPS NY
5.5%
52W%
47.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+277.1% upside
Upside
+277.1%
Quality
14
Fate Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 161
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
FATE
Latest News
—
Caricamento notizie per FATE…
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading